In the BioHarmony Drug Report Database
Gabapentin enacarbil
Horizant (gabapentin enacarbil) is a small molecule pharmaceutical. Gabapentin enacarbil was first approved as Horizant on 2011-04-06. It is used to treat bipolar disorder, epilepsy, partial epilepsies, phobic disorders, and postherpetic neuralgia in the USA. Horizant’s patents are valid until 2029-06-10 (FDA).
Trade Name
|
Horizant |
|---|---|
Common Name
|
gabapentin enacarbil |
ChEMBL ID
|
CHEMBL1628502 |
Indication
|
bipolar disorder, epilepsy, partial epilepsies, phobic disorders, postherpetic neuralgia |
Drug Class
|
Gabamimetics |
Image (chem structure or protein)